PharmaKure announces collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases

New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions

04-Mar-2024 - PharmaKure announces a new epigenetics collaboration with Sheffield Hallam University. This partnership will focus on ‘gene-based environmental biomarkers’, known as epigenetic markers, for calculating risk scores for Alzheimer’s diseases. Together withALZmetrixTM, PharmaKure’s blood-based ...

Cromatic closes $5.3 million to modernize life science R&D outsourcing

Proprietary outsourcing platform aims to get biotechs off the ground with fast and seamless CRO matching

16-Nov-2023 - Cromatic, a full-stack digital platform for outsourced life sciences research, announced it has closed $5.3 million in funding. LifeX Ventures and AgFunder led the round with participation from Work Life Ventures, Not Boring Capital, FJ Labs, What If Ventures, Lux Capital, and angel ...

Bioprinting breakthrough will let scientists print their own proteins at their benchtop

Nuclera raises $42.5M in first close of Series B for desktop protein printer

07-Feb-2022 - Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, announced that the first close of its Series B financing has raised $42.5 million. The funds raised will be used to accelerate the development and commercialization of its eProtein™ desktop ...

CRISPR-Cas9 corrects sickle cell mutation

Collaborative effort to reduce off-target CRISPR-Cas9 genome editing

08-Aug-2018 - Genome editing using the CRISPR-Cas9 system has tremendous promise for therapeutic correction of genetic errors in human cells. Prior to adoption as a medical therapeutic, safety concerns relating to off-target effects must be minimized to mitigate risks that may arise from the unintended action ...

BioAscent receives funding for its integrated drug discovery services

28-Jun-2018 - BioAscent has secured £1.6m in funding from Maven Capital Partners (“Maven”). The investment will facilitate BioAscent’s growth through its unique offering of integrated drug discovery, and compound management services, as well as the Compound Cloud library of lead-like pharma compounds, from its ...

New test could identify resistant tuberculosis faster

19-May-2015 - The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team. This could help health service providers to better treat disease, control transmission of this infection, and ...

IDT Opens Molecular Biology R&D Facility in Redwood City

Dr Caifu Chen to lead new product development at California site

30-Apr-2015 - Research and development for Integrated DNA Technologies' (IDT) validated molecular biology products will now be performed in a newly built facility in Redwood City, California. The 8,000 square foot building houses state-of-the-art labs that will allow IDT scientists to maximize the company’s ...

IDT’s San Diego Manufacturing Facility Receives ISO 14001 Certification

27-Apr-2015 - Integrated DNA Technologies (IDT) announces that its San Diego, California, manufacturing facility has attained ISO 14001:2004 certification for its environmental management systems. Now, both of IDT’s US manufacturing sites (Coralville, IA and San Diego, CA) have ISO 14001 certified ...

Seward appoints Dan Crothers as Managing Director

21-Jan-2015 - Seward Ltd. announced the appointment of Dan Crothers as Managing Director to direct strategy and implement a series of new developments within the Company. Dan, who has worked with Seward since 2008, assumes the new role after success in previous positions, including managing Seward’s Singapore ...

Advanced Cell Diagnostics Appoints Tom Olenic as Chief Commercial Officer

04-Dec-2014 - Advanced Cell Diagnostics, Inc. (ACD) announced the appointment of Tom Olenic to its executive leadership team as Chief Commercial Officer.Mr. Olenic has more than 25 years’ commercial and executive management experience in the biotechnology industry. Prior to joining ACD, Tom was General Manager ...